Helix Biopharma Corp Stock Performance
| HBP Stock | CAD 0.77 0.07 10.00% |
The company retains a Market Volatility (i.e., Beta) of -1.83, which attests to a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Helix BioPharma are expected to decrease by larger amounts. On the other hand, during market turmoil, Helix BioPharma is expected to outperform it. At this point, Helix BioPharma Corp has a negative expected return of -0.33%. Please make sure to check out Helix BioPharma's value at risk and the relationship between the accumulation distribution and relative strength index , to decide if Helix BioPharma Corp performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Helix BioPharma Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Last Split Factor 1:5 | Last Split Date 2024-08-16 |
1 | Helix BioPharma Stock Price Down 11.6 percent - Time to Sell - MarketBeat | 10/29/2024 |
2 | Helix BioPharma Corp. Announces Resignation of Praveen Varshney as Chief Financial Officer - Marketscreener.com | 11/21/2024 |
| Begin Period Cash Flow | 808 K |
Helix |
Helix BioPharma Relative Risk vs. Return Landscape
If you would invest 115.00 in Helix BioPharma Corp on August 25, 2024 and sell it today you would lose (38.00) from holding Helix BioPharma Corp or give up 33.04% of portfolio value over 90 days. Helix BioPharma Corp is producing return of less than zero assuming 8.1158% volatility of returns over the 90 days investment horizon. Simply put, 72% of all stocks have less volatile historical return distribution than Helix BioPharma, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Helix BioPharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Helix BioPharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Helix BioPharma Corp, and traders can use it to determine the average amount a Helix BioPharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0403
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | HBP |
Estimated Market Risk
| 8.12 actual daily | 72 72% of assets are less volatile |
Expected Return
| -0.33 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Helix BioPharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Helix BioPharma by adding Helix BioPharma to a well-diversified portfolio.
Helix BioPharma Fundamentals Growth
Helix Stock prices reflect investors' perceptions of the future prospects and financial health of Helix BioPharma, and Helix BioPharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Helix Stock performance.
| Return On Equity | -22.21 | ||||
| Return On Asset | -4.59 | ||||
| Current Valuation | 36.67 M | ||||
| Shares Outstanding | 49.02 M | ||||
| Price To Earning | (7.09) X | ||||
| Price To Book | 77.46 X | ||||
| EBITDA | (9.22 M) | ||||
| Net Income | (9.26 M) | ||||
| Cash And Equivalents | 938 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 1.58 M | ||||
| Current Ratio | 0.37 X | ||||
| Book Value Per Share | (0) X | ||||
| Cash Flow From Operations | (5.22 M) | ||||
| Earnings Per Share | (1.05) X | ||||
| Market Capitalization | 37.75 M | ||||
| Total Asset | 1.49 M | ||||
| Retained Earnings | (210.67 M) | ||||
| Working Capital | (123 K) | ||||
About Helix BioPharma Performance
By examining Helix BioPharma's fundamental ratios, stakeholders can obtain critical insights into Helix BioPharma's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Helix BioPharma is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 4.5 K | 4.7 K | |
| Return On Tangible Assets | (6.22) | (5.91) | |
| Return On Capital Employed | 104.12 | 109.33 | |
| Return On Assets | (6.22) | (5.91) | |
| Return On Equity | 102.93 | 108.08 |
Things to note about Helix BioPharma Corp performance evaluation
Checking the ongoing alerts about Helix BioPharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Helix BioPharma Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Helix BioPharma Corp generated a negative expected return over the last 90 days | |
| Helix BioPharma Corp has high historical volatility and very poor performance | |
| Helix BioPharma Corp has some characteristics of a very speculative penny stock | |
| Helix BioPharma Corp has high likelihood to experience some financial distress in the next 2 years | |
| Helix BioPharma Corp has accumulated 1.58 M in total debt. Helix BioPharma Corp has a current ratio of 0.36, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Helix BioPharma until it has trouble settling it off, either with new capital or with free cash flow. So, Helix BioPharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Helix BioPharma Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Helix to invest in growth at high rates of return. When we think about Helix BioPharma's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (9.26 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Helix BioPharma Corp has accumulated about 938 K in cash with (5.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Latest headline from news.google.com: Helix BioPharma Corp. Announces Resignation of Praveen Varshney as Chief Financial Officer - Marketscreener.com |
- Analyzing Helix BioPharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Helix BioPharma's stock is overvalued or undervalued compared to its peers.
- Examining Helix BioPharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Helix BioPharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Helix BioPharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Helix BioPharma's stock. These opinions can provide insight into Helix BioPharma's potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Helix Stock
Helix BioPharma financial ratios help investors to determine whether Helix Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Helix with respect to the benefits of owning Helix BioPharma security.